(ICUI) ICU Medical - Overview
Stock: Infusion Devices, Vascular Access, IV Solutions, Infusion Pumps, Safety Software
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.8% |
| Relative Tail Risk | -12.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.04 |
| Alpha | -19.78 |
| Character TTM | |
|---|---|
| Beta | 0.964 |
| Beta Downside | 0.685 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.23% |
| CAGR/Max DD | -0.08 |
Description: ICUI ICU Medical January 11, 2026
ICU Medical (NASDAQ:ICUI) designs, manufactures and sells a broad portfolio of infusion-therapy, vascular-access and critical-care devices, ranging from needle-free connectors (MicroClave, NanoClave) and closed-system drug-transfer kits (ChemoLock, ChemoClave) to smart infusion pumps (Plum 360, Plum Duo) and medication-management software (MedNet, LifeShield). Its product set serves acute-care hospitals, ambulatory clinics, home-health and long-term-care providers across the United States and globally.
In its most recent fiscal quarter (Q4 2023), ICU Medical reported revenue of roughly $1.0 billion, up about 9 % year-over-year, with an operating margin of 12 % and a free-cash-flow conversion of 85 %. The company’s growth is being driven by expanding outpatient infusion services, an aging patient base that increases demand for safe drug-administration systems, and a favorable regulatory climate that rewards needle-free and closed-system technologies. The broader health-care supplies sector is also benefitting from a 4-5 % annual rise in U.S. hospital spending on infusion and medication-safety solutions.
For a data-rich, unbiased view of ICU Medical’s valuation dynamics, you may find ValueRay’s analyst toolkit worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -7.36m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.32 > 1.0 |
| NWC/Revenue: 30.79% < 20% (prev 30.28%; Δ 0.51% < -1%) |
| CFO/TA 0.04 > 3% & CFO 159.4m > Net Income -7.36m |
| Net Debt (1.06b) to EBITDA (324.2m): 3.28 < 3 |
| Current Ratio: 2.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (24.7m) vs 12m ago 1.01% < -2% |
| Gross Margin: 36.47% > 18% (prev 0.33%; Δ 3614 % > 0.5%) |
| Asset Turnover: 55.19% > 50% (prev 54.36%; Δ 0.84% > 0%) |
| Interest Coverage Ratio: 1.24 > 6 (EBITDA TTM 324.2m / Interest Expense TTM 98.1m) |
Altman Z'' 2.26
| A: 0.17 (Total Current Assets 1.21b - Total Current Liabilities 492.9m) / Total Assets 4.10b |
| B: 0.17 (Retained Earnings 706.6m / Total Assets 4.10b) |
| C: 0.03 (EBIT TTM 121.3m / Avg Total Assets 4.20b) |
| D: 0.34 (Book Value of Equity 676.1m / Total Liabilities 1.98b) |
| Altman-Z'' Score: 2.26 = BBB |
Beneish M -3.05
| DSRI: 1.10 (Receivables 217.2m/198.8m, Revenue 2.32b/2.34b) |
| GMI: 0.90 (GM 36.47% / 32.87%) |
| AQI: 1.05 (AQ_t 0.58 / AQ_t-1 0.55) |
| SGI: 0.99 (Revenue 2.32b / 2.34b) |
| TATA: -0.04 (NI -7.36m - CFO 159.4m) / TA 4.10b) |
| Beneish M-Score: -3.05 (Cap -4..+1) = AA |
What is the price of ICUI shares?
Over the past week, the price has changed by +1.79%, over one month by +1.66%, over three months by +10.72% and over the past year by -3.52%.
Is ICUI a buy, sell or hold?
- StrongBuy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ICUI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 180.8 | 17.3% |
| Analysts Target Price | 180.8 | 17.3% |
| ValueRay Target Price | 160.2 | 3.9% |
ICUI Fundamental Data Overview February 03, 2026
P/S = 1.5948
P/B = 1.7411
P/EG = 1.6985
Revenue TTM = 2.32b USD
EBIT TTM = 121.3m USD
EBITDA TTM = 324.2m USD
Long Term Debt = 1.31b USD (from longTermDebt, last quarter)
Short Term Debt = 15.6m USD (from shortTermDebt, last quarter)
Debt = 1.36b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.06b USD (from netDebt column, last quarter)
Enterprise Value = 4.77b USD (3.70b + Debt 1.36b - CCE 299.7m)
Interest Coverage Ratio = 1.24 (Ebit TTM 121.3m / Interest Expense TTM 98.1m)
EV/FCF = 70.98x (Enterprise Value 4.77b / FCF TTM 67.1m)
FCF Yield = 1.41% (FCF TTM 67.1m / Enterprise Value 4.77b)
FCF Margin = 2.89% (FCF TTM 67.1m / Revenue TTM 2.32b)
Net Margin = -0.32% (Net Income TTM -7.36m / Revenue TTM 2.32b)
Gross Margin = 36.47% ((Revenue TTM 2.32b - Cost of Revenue TTM 1.47b) / Revenue TTM)
Gross Margin QoQ = 37.41% (prev 37.91%)
Tobins Q-Ratio = 1.16 (Enterprise Value 4.77b / Total Assets 4.10b)
Interest Expense / Debt = 1.45% (Interest Expense 19.8m / Debt 1.36b)
Taxrate = 21.0% (US default 21%)
NOPAT = 95.8m (EBIT 121.3m * (1 - 21.00%))
Current Ratio = 2.45 (Total Current Assets 1.21b / Total Current Liabilities 492.9m)
Debt / Equity = 0.64 (Debt 1.36b / totalStockholderEquity, last quarter 2.13b)
Debt / EBITDA = 3.28 (Net Debt 1.06b / EBITDA 324.2m)
Debt / FCF = 15.86 (Net Debt 1.06b / FCF TTM 67.1m)
Total Stockholder Equity = 2.05b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.18% (Net Income -7.36m / Total Assets 4.10b)
RoE = -0.36% (Net Income TTM -7.36m / Total Stockholder Equity 2.05b)
RoCE = 3.61% (EBIT 121.3m / Capital Employed (Equity 2.05b + L.T.Debt 1.31b))
RoIC = 2.74% (NOPAT 95.8m / Invested Capital 3.49b)
WACC = 7.23% (E(3.70b)/V(5.07b) * Re(9.47%) + D(1.36b)/V(5.07b) * Rd(1.45%) * (1-Tc(0.21)))
Discount Rate = 9.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.12%
[DCF Debug] Terminal Value 73.89% ; FCFF base≈108.4m ; Y1≈71.1m ; Y5≈32.5m
Fair Price DCF = N/A (negative equity: EV 736.9m - Net Debt 1.06b = -327.9m; debt exceeds intrinsic value)
EPS Correlation: -34.64 | EPS CAGR: -48.91% | SUE: -4.0 | # QB: 0
Revenue Correlation: 44.65 | Revenue CAGR: 12.91% | SUE: 1.16 | # QB: 1
EPS next Quarter (2026-03-31): EPS=1.79 | Chg30d=-0.013 | Revisions Net=-2 | Analysts=3
EPS next Year (2026-12-31): EPS=8.01 | Chg30d=-0.033 | Revisions Net=-1 | Growth EPS=+5.9% | Growth Revenue=-1.3%